Docusate
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Docusate: Stool-softening anionic surfactant → Plummer-Vinson syndrome
One-Sentence Summary
Docusate is an anionic surfactant stool softener. The TxGNN model predicts it may be relevant for Plummer-Vinson syndrome, with a score of 0.9918. However, no clinical trials and no publications were found that support this direction, so the prediction rests on the model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Plummer-Vinson syndrome |
| TxGNN Prediction Score | 0.9918 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (2 of 2) – CDSCO approval status is not included in this data |
| Number of Listed Products | 2 (valid: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for docusate is not available in the data compiled for this report. Docusate is known as a stool softener (an anionic surfactant). It has no known effect on iron absorption, blood cell formation, or the esophageal web that characterizes Plummer-Vinson syndrome.
The high score most likely reflects how close Plummer-Vinson syndrome sits to anemia-related terms (such as iron deficiency anemia), because the syndrome typically presents with iron deficiency anemia, difficulty swallowing and esophageal webs. This looks like a pattern of association in the model rather than a true pharmacological link. The anemia-related terms linked to docusate may also come from combination products in which docusate is paired with iron or folate to offset constipation, rather than from any anti-anemic action of docusate itself.
Overall, the prediction should be treated as a weak hypothesis with no mechanistic support at present.
Safety Considerations
- Drug Interactions (4 recorded):
- Lactulose: Moderate
- Mineral oil: Moderate
- Phenolphthalein: Moderate
- Linaclotide: Minor
These are mostly other laxatives, so combined use may add to laxative effects.
Package-insert warnings and contraindications are not available in the data compiled for this report. Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a very high model score (0.9918) but no clinical trials or literature, and no plausible mechanism links a stool softener to Plummer-Vinson syndrome. The evidence level is L5 (model prediction only).
To proceed, the following is needed:
- Mechanism-of-action data for docusate and a testable biological rationale for Plummer-Vinson syndrome
- Package-insert warnings and contraindications from the local regulator
- Any preclinical or clinical study that directly addresses Plummer-Vinson syndrome
- Clarification of whether the anemia-related associations come from combination products rather than docusate itself
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.